| scholarly article | Q13442814 |
| P50 | author | Glen M. Boyle | Q37610927 |
| Mitchell S. Stark | Q54836800 | ||
| Vanessa F Bonazzi | Q55303023 | ||
| Robert Ballotti | Q56451905 | ||
| Christopher W. Schmidt | Q73249629 | ||
| Nicholas Hayward | Q91316185 | ||
| P2093 | author name string | Pamela M Pollock | |
| Jane M Palmer | |||
| Judith Symmons | |||
| Adrian C Herington | |||
| Catherine M Lanagan | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| A landscape of driver mutations in melanoma | Q24603357 | ||
| Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma | Q24607661 | ||
| A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence | Q24652491 | ||
| Elucidating distinct roles for NF1 in melanomagenesis | Q27851952 | ||
| A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition | Q27852017 | ||
| Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence | Q27852894 | ||
| Characterization of the Melanoma miRNAome by Deep Sequencing | Q28473165 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. | Q30497690 | ||
| A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability | Q31087541 | ||
| Imperfect centered miRNA binding sites are common and can mediate repression of target mRNAs | Q33742561 | ||
| Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis | Q33962607 | ||
| A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth | Q34210051 | ||
| miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein | Q34947386 | ||
| In-depth characterization of microRNA transcriptome in melanoma | Q34984013 | ||
| MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin | Q35075757 | ||
| Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma | Q35596369 | ||
| A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma | Q35699278 | ||
| In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. | Q36284875 | ||
| Histology-specific microRNA alterations in melanoma | Q36828567 | ||
| Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma | Q37104104 | ||
| Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. | Q37435516 | ||
| MicroRNA regulation of melanoma progression. | Q37972483 | ||
| Loss of microRNA-205 expression is associated with melanoma progression | Q38325937 | ||
| Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo | Q39158531 | ||
| Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors | Q39416723 | ||
| Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. | Q39712781 | ||
| miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma | Q39884642 | ||
| Characterization of microRNA expression levels and their biological correlates in human cancer cell lines | Q40158414 | ||
| Functional microRNA targets in protein coding sequences | Q42634002 | ||
| Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. | Q45241998 | ||
| Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression | Q46106828 | ||
| Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. | Q53259136 | ||
| MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. | Q55069393 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 17753-17763 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma | |
| P478 | volume | 6 |
| Q41763210 | Circulating microRNAs as Candidate Biomarkers for the Surveillance of Melanoma Patients |
| Q41862341 | Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells |
| Q40072818 | Discovery and characterization of the feline miRNAome |
| Q38704732 | Downregulation of miR-493 promoted melanoma proliferation by suppressing IRS4 expression |
| Q52584369 | Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. |
| Q89967618 | Melanoma in the Eyes of Mechanobiology |
| Q47209993 | MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma |
| Q61417351 | MiRNAs in Malignant Melanoma |
| Q48293862 | MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. |
| Q38700186 | MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2. |
| Q51091113 | MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC. |
| Q38548766 | MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer |
| Q50062795 | MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention. |
| Q90149506 | MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours |
| Q39101272 | MicroRNAs in melanoma development and resistance to target therapy |
| Q92618072 | Neurofibromin 1 expression is negatively correlated with malignancy and prognosis of epithelial ovarian cancer |
| Q59136531 | New insights in melanoma resistance to BRAF inhibitors: a role for microRNAs |
| Q36782461 | Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b |
| Q64269751 | Prognostic significance of deregulated microRNAs in uveal melanomas |
| Q64119763 | Role of miRNAs in Melanoma Metastasis |
| Q48203955 | Sex disparity in cancer: roles of microRNAs and related functional players. |
| Q41700266 | Small Non-coding RNA Abundance in Adrenocortical Carcinoma: A Footprint of a Rare Cancer. |
| Q37580297 | The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor |
| Q35947544 | The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis |
| Q55004983 | The distinct role of strand-specific miR-514b-3p and miR-514b-5p in colorectal cancer metastasis. |
| Q50019429 | Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF. |
| Q49921953 | miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma |
| Q47134272 | miR-514a-3p functions as a tumor suppressor in renal cell carcinoma. |
| Q37619788 | miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways |
| Q89697863 | miRNAs as Key Players in the Management of Cutaneous Melanoma |
| Q37362485 | microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. |
| Q39393665 | scan_tcga tools for integrated epigenomic and transcriptomic analysis of tumor subgroups |
Search more.